JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
Add like
Add dislike
Add to saved papers

Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.

Neurosurgery 2008 June
OBJECTIVE: Vestibular schwannomas (VS) are common, benign, VIIIth cranial nerve tumors. Treatment in patients with the genetic disorder neurofibromatosis type II (NF2) is complicated by their development of bilateral VS and risk of complete deafness. Intervention decisions consider several clinical factors including tumor size and growth rate evaluated using magnetic resonance imaging. The current study evaluated the relative sensitivity of volumetric versus linear diameter measurement for assessing VS growth rate and progression.

METHODS: Retrospective analysis was performed on 43 magnetic resonance imaging scans acquired longitudinally (range, 2-7 yr) from 10 patients with NF2. Fifteen VS were measured (five patients had unilateral lesions meeting inclusion criteria) using both maximum linear diameter and semiautomated volumetric analysis. Progression was defined according to Response Evaluation Criteria in Solid Tumors and its volumetric (cubed linear) equivalent. Measurement techniques were compared by assessing sensitivity to lesion growth.

RESULTS: Volumetric measures were significantly more sensitive to VS growth, both for total change and change per year percentages; cubed linear growth measures (proportional to volume growth) underestimated volume growth by 50%. Seven lesions showed progression on volumetric analysis, but two of these did not show progression based on linear measures. Thus, for 29% of lesions showing progression based on volume, linear measures did not detect progression.

CONCLUSION: Linear measurements underestimate VS growth rate compared with volumetric measures in NF2 patients. These results provide clear, quantitative proof that diameter measures are not as sensitive to change as volumetric measurements and that volumetric measurements should be strongly considered when making VS treatment decisions.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app